Turku PET Centre
- Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden (2023)
- Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies (2024)
- Plasma cell-free DNA methylation marks for episodic memory impairment: a pilot twin study (2020)
- Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis (2025)
- Plasma CHI3L1 associates with increased TSPO-PET measurable microglial activation in patients with progressive multiple sclerosis (2024)
- Plasma Levels of Endocannabinoids and Their Analogues Are Related to Specific Fecal Bacterial Genera in Young Adults: Role in Gut Barrier Integrity (2022)
- Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals (2021)
- Plasma lipidomics and coronary plaque changes: a substudy of the SMARTool clinical trial (2024)
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease (2024)
- Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of Ga-68 Bombesin Antagonist BAY 86-7548 in Healthy Men (2013)





